FDA accepts Rasilez NDA

FDA accepted for filing an NDA from Novartis (NVS; SWX:NOVN) for Rasilez aliskiren ( SPP100) to treat hypertension. The PDUFA date for the renin inhibitor is undisclosed. NVS in-licensed Rasilez from ...